Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label pediatric linaclotide safety study in functional constipation or IBS-C
NL-OMON52547Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of linaclotide in functional constipation (FC) and irritable bowel syndrome (IBS) (2 cohorts), sponsored by AbbVie Inc. Primary endpoint: Long-term safety assessments. Started Feb 2022; status: completed.
02
Drugs
linaclotide
03
Conditions
functional constipation (FC)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NL-OMON52547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52547.